Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term GrowthBenzinga • 11/12/24
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth ProspectsSeeking Alpha • 11/12/24
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/22/24
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and MoreGlobeNewsWire • 10/14/24
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic ManufacturingBusiness Wire • 06/03/24